Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Potential Federal Drug Savings Could Propel Biosimilars Bill

Executive Summary

The potential for biosimilars to lower Medicare and Medicaid drug spending could help catalyze support for a follow-on biologics bill this year, a Capitol Hill staffer predicted at the Food and Drug Law Institute's annual conference March 26

You may also be interested in...



Canada Biosimilars Proposal Requires Extra Studies To Show Substitutability

Substitution of a biosimilar for its reference brand product would not be automatic under the framework proposed by Health Canada for approving what it calls "subsequent entry biologics.

Canada Biosimilars Proposal Requires Extra Studies To Show Substitutability

Substitution of a biosimilar for its reference brand product would not be automatic under the framework proposed by Health Canada for approving what it calls "subsequent entry biologics.

Biosimilars Bill From Reps. Eshoo, Barton Gathers Steam In House Cmte.

The counter-intuitive political dynamics of the follow-on biologics debate in the House Energy and Commerce Committee are on full display with the introduction of a bill from Rep. Anna Eshoo, D-Calif., and Joe Barton, R-Texas

Related Content

UsernamePublicRestriction

Register

PS049461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel